Pulmatrix (NSDQ:PULM) announced today that it completed an offering with gross proceeds of approximately $40 million.
Lexington, Mass.-based Pulmatrix said in a news release that it completed the registered direct offering to extend the company’s cash runway.
Now, the company has additional financing to help fully fund data readouts across its development pipeline, which includes a Phase 1b study for its PUR1800 therapeutic, a Phase 1/2 study for PUR3100 and a Phase 2b study for Pulmazole.
Get the full story at our sister site, Drug Delivery Business News.